Cardiovascular Systems, Aerolase ink joint laser atherectomy dev deal

Cardiovascular Systems (NSDQ:CSII) said today that it inked an agreement with Aerolase to develop a laser atherectomy system designed for treating multiple arterial diseases. As part of the agreement, St. Paul, Minn.-based Cardiovascular Systems said it made an undisclosed equity investment in Aerolase, and agreed to make more milestone-dependent investments in the company. “We are excited to pursue the development of an atherectomy laser device with an industry-leading company like CSI. Our dermatology and aesthetic medicine customers appreciate the portability, reliability, ease-of-use and minimal set up time that our lasers offer in addition to high clinical efficacies. We look forward to demonstrating that our solid-state, patented, air-cooled laser technology can transfer to atherectomy and provide similar benefits to interventional cardiologists,”Aerolase chair & CEO Pavel Efremkin said in a press release. “We believe there is an opportunity to leverage Aerolase’s innovative proprietary laser technology, which is FDA-cleared for dermatology and medical aesthetic uses, and supported by leading physicians in those fields. The collaboration project aims to create a significant improvement in the quality of care for patients suffering from peripheral arterial disease and in-stent restenosis. The successful development and commercialization of this laser atherectomy technology will expand the number of patients CSI serves. We are committed to transfo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Research & Development Vascular aerolase Cardiovascular Systems Inc. Source Type: news